Safety and efficacy of transcatheter arterial embolization for management of refractory hematuria of prostatic origin  

作　　者：Jinlong Zhang Quanyu Wang Hongwei Zhao Bing Yuan Xuedong Sun Yang Guan Zhuting Fang Maoqiang Wang 

机构地区：[1]Department of Radiology,Bejing Tongren Hospital,Capital Medical University,Bejing 100730,China [2]Intrventional Department,Huabei Petroleum General Hospital,Rengu,062552,China [3]Departments of Interentional Radiology,Chinese PLA General Hospital,Bejfing,100853,PR China [4]Shengli Clinical Medical College of Pujian Medical University,Fuchou,350122,PR China [5]Deparment of Intervendional Radiology,Fyjian Provincial Hopital,Fuzhou,350001,PR China

出　　处：《Journal of Interventional Medicine》2022年第2期84-88,共5页介入医学杂志（英文）

基　　金：the National Natural Science Foundation of China (82072023);the Fujian Province Natural Science Fund Project (2020J011096 and 2020J011064)。

摘　　要：Objective: To estimate the safety and efficacy of transcatheter arterial embolization(TAE) in the treatment of refractory hematuria of prostatic origin(RHPO).Methods: This retrospective study included 23 patients who underwent TAE for RHPO between May 2013 and August 2021. Technical and clinical success rates were calculated, and arteriogram findings and complications were detected.Results: Embolization was performed 24 times in 23 patients. Technical success was achieved in 24/24(100%)embolization procedures. Contrast agent extravasation was detected during 2 of the 24 angiographic procedures.Bilateral embolization was performed in 23(95.8%) of the 24 procedures. The clinical success rate was 21/23(91.3%), and hematuria stopped 1–4 days after TAE. No serious complications were observed.Conclusion: TAE is a safe and effective minimally invasive technique for treating patients with RHPO.

关 键 词：Transcatheter arterial embolization HEMATURIA Benign prostatic hyperplasia 

分 类 号：R699[医药卫生—泌尿科学]